Significance of myositis-specific autoantibodies (MSA) for clinical features in polymyositis/dermatomyositis-associated interstitial lung disease
Not Applicable
Recruiting
- Conditions
- Polymyositis/dermatomyositis/clinically amyopathic dermatomyositis-associated Interstitial lung disease
- Registration Number
- JPRN-UMIN000022605
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are unable to get informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical feature and overall survival according to MSA status
- Secondary Outcome Measures
Name Time Method Prevalence of each myositis-specific autoantibodies Change of pulmonary function tests, chest HRCT findings and laboratory findings during follow up period (3 years) Comparison of therapeutic regimen